Journey with AxxessBio:
Stay informed with our latest news, press releases and shared milestones
Latest News and Releases
June 2014, AxxessBio and GC Pharma (formerly Green Cross Corporation) signed an exclusive agreement to supply Hunterase in Malaysia. Hunterase is an enzyme replacement therapy for Hunter Syndrome also known as Mucopolysaccharidosis II (MPS II). MPS II is a very rare inherited disease affecting mostly males. The individual is born with
Since December 1st 2014, AxxessBio moved the regional head-office to a central location in Singapore, 36 Purvis Street, very near key landmarks like Raffles Hotel, Suntec City and the new Southbeach development. This is a key milestone in the expansion of AxxessBio. With this move, AxxessBio has grown in
Interested in Partnering Up?
At AxxessBio, we are continuously looking for partnerships to bring new innovative therapies for patients all around Asia
About Us
We bring innovative therapies & diagnostics to patients with rare diseases or unmet medical needs.
Address:
AxxessBio Pte Ltd, 36 Purvis Street, #02-05, Singapore 188613
Phone:
+65 6334 2518
Email:
Social:
AxxessBio is pleased to share that GENCEBOK® (caffeine citrate) 10 MG/ML SOLUTION FOR INFUSION has been approved by the Health Sciences Authority (HSA) Singapore for apnoea of prematurity. GENCEBOK® is
Google Maps
© 2022 AxxessBio Pte Ltd. All Rights Reserved. Our Privacy Policy.